2.6(top 20%)
impact factor
2.6K(top 10%)
papers
45.8K(top 10%)
citations
85(top 10%)
h-index
2.7(top 20%)
extended IF
2.9K
all documents
49.4K
doc citations
118(top 10%)
g-index

Top Articles

#TitleJournalYearCitations
1HER2 Amplification Ratios by Fluorescence In Situ Hybridization and Correlation with Immunohistochemistry in a Cohort of 6556 Breast Cancer TissuesClinical Breast Cancer2004583
2Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast CancerClinical Breast Cancer2009559
3The Global Breast Cancer Burden: Variations in Epidemiology and SurvivalClinical Breast Cancer2005462
4Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial DesignClinical Breast Cancer2009379
5Evaluation of Clinical Outcomes According to HER2 Detection by Fluorescence In Situ Hybridization in Women with Metastatic Breast Cancer Treated with TrastuzumabClinical Breast Cancer2005330
6TAILORx: Trial Assigning Individualized Options for Treatment (Rx)Clinical Breast Cancer2006244
7Cognitive Training for Improving Executive Function in Chemotherapy-Treated Breast Cancer SurvivorsClinical Breast Cancer2013243
8Stress Management and Resilience Training (SMART) Program to Decrease Stress and Enhance Resilience Among Breast Cancer Survivors: A Pilot Randomized Clinical TrialClinical Breast Cancer2011230
9Insulin-Lowering Effects of Metformin in Women with Early Breast CancerClinical Breast Cancer2008219
10Classification, Treatment Strategy, and Associated Drug Resistance in Breast CancerClinical Breast Cancer2016203
11Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up ResultsClinical Breast Cancer2009196
12Genetic Markers in Triple-Negative Breast CancerClinical Breast Cancer2018165
13Phase II Study of Weekly Albumin-Bound Paclitaxel for Patients with Metastatic Breast Cancer Heavily Pretreated with TaxanesClinical Breast Cancer2007164
14Neoadjuvant Docetaxel in Breast Cancer: 3-Year Survival Results from the Aberdeen TrialClinical Breast Cancer2002155
15Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET TrialClinical Breast Cancer2021155
16Serum Interleukin 6, Plasma VEGF, Serum VEGF, and VEGF Platelet Load in Breast Cancer PatientsClinical Breast Cancer2002149
17Molecular Mechanisms of Breast Cancer Metastases to BoneClinical Breast Cancer2005149
18Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation TreatmentClinical Breast Cancer2013147
19Results of a Diet/Exercise Feasibility Trial to Prevent Adverse Body Composition Change in Breast Cancer Patients on Adjuvant ChemotherapyClinical Breast Cancer2008143
20Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor BurdenClinical Breast Cancer2007142
21Metastasis Suppressor Genes: Basic Biology and Potential Clinical UseClinical Breast Cancer2003141
22Basal Breast Cancer Molecular Subtype Predicts for Lower Incidence of Axillary Lymph Node Metastases in Primary Breast CancerClinical Breast Cancer2008137
23Breast Cancer Chemotherapy-Related Cognitive DysfunctionClinical Breast Cancer2002136
24Two Concurrent Phase II Trials of Paclitaxel/Carboplatin/Trastuzumab (Weekly or Every-3-Week Schedule) as First-Line Therapy in Women with HER2-Overexpressing Metastatic Breast Cancer: NCCTG Study 983252Clinical Breast Cancer2005136
25Metastatic Breast Cancer: The Treatment ChallengeClinical Breast Cancer2008136
26The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled TrialClinical Breast Cancer2010136
27Peripheral Neuropathy with Microtubule-Targeting Agents: Occurrence and Management ApproachClinical Breast Cancer2011133
28Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the OutcomeClinical Breast Cancer2013132
29Mammalian Target of Rapamycin: A New Molecular Target for Breast CancerClinical Breast Cancer2003131
30Review of Factors Influencing Women's Choice of Mastectomy Versus Breast Conserving Therapy in Early Stage Breast Cancer: A Systematic ReviewClinical Breast Cancer2018130
31CLEOPATRA: A Phase III Evaluation of Pertuzumab and Trastuzumab for HER2-Positive Metastatic Breast CancerClinical Breast Cancer2010129
32A Novel Approach Toward Development of a Rapid Blood Test for Breast CancerClinical Breast Cancer2003128
33Adjuvant Chemotherapy for Breast Cancer: Effects on Cerebral White Matter Seen in Diffusion Tensor ImagingClinical Breast Cancer2008127
34Use of Trastuzumab Beyond Disease Progression: Observations from a Retrospective Review of Case HistoriesClinical Breast Cancer2004124
35Breast Cancer Classification According to Immunohistochemistry Markers: Subtypes and Association With Clinicopathologic Variables in a Peruvian Hospital DatabaseClinical Breast Cancer2010124
36Treatment of Metastatic Breast Cancer with Trastuzumab and Vinorelbine During PregnancyClinical Breast Cancer2005123
37Randomized Phase II Trial of the Cyclin-Dependent Kinase Inhibitor Dinaciclib (MK-7965) Versus Capecitabine in Patients With Advanced Breast CancerClinical Breast Cancer2014123
38E2100: A Phase III Trial of Paclitaxel Versus Paclitaxel/Bevacizumab for Metastatic Breast CancerClinical Breast Cancer2003122
39Aromatase Inhibitor–Associated Arthralgia and/or Bone Pain: Frequency and Characterization in Non–Clinical Trial PatientsClinical Breast Cancer2007121
40Phase II Trial of Saracatinib (AZD0530), an Oral SRC-inhibitor for the Treatment of Patients with Hormone Receptor-negative Metastatic Breast CancerClinical Breast Cancer2011121
41Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and PathogenesisClinical Breast Cancer2010120
42Phase II Study of Trastuzumab plus Gemcitabine in Chemotherapy-Pretreated Patients with Metastatic Breast CancerClinical Breast Cancer2004118
43Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-Month Analysis of the E-ZO-FAST TrialClinical Breast Cancer2012118
44The Global and Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysisClinical Breast Cancer2019117
45Effects of Tai Chi Chuan on Insulin and Cytokine Levels in a Randomized Controlled Pilot Study on Breast Cancer SurvivorsClinical Breast Cancer2011116
46Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label TrialClinical Breast Cancer2011113
47Internet Usage Among Women with Breast Cancer: An Exploratory StudyClinical Breast Cancer2000112
48Alarming Burden of Triple-Negative Breast Cancer in IndiaClinical Breast Cancer2018112
49Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of LiteratureClinical Breast Cancer2017111
50Feasibility of Quantifying the Effects of Epoetin Alfa Therapy on Cognitive Function in Women with Breast Cancer Undergoing Adjuvant or Neoadjuvant ChemotherapyClinical Breast Cancer2005110